Join
Live feed
·
INSIDERFilingvia Quantisnow
Neoleukin Therapeutics Inc. logo

SEC Form 4: Walkey Carl sold $13,308 worth of Common Stock (1,200 units at $11.09), decreasing direct ownership by 0.09% to 1,354,762 units

ByQuantisnow·Wall Street's wire, on your screen.
NLTX· Neoleukin Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NLTX (Neoleukin Therapeutics Inc.) and more on Quantisnow.